V1RD16 Inhibitors
V1RD16 inhibitors pertain to a class of chemical compounds designed to selectively interact with specific biological targets known as V1RD16 proteins. These proteins may be involved in a myriad of complex biochemical pathways within organisms. The inhibitors are synthesized through a process that aims to ensure high affinity and specificity to the V1RD16 proteins, which is a critical aspect of their function. The chemical structure of V1RD16 inhibitors is typically characterized by the presence of certain moieties or functional groups that enable the binding to the active or allosteric sites of the V1RD16 proteins. This binding can result in the modulation of the protein's activity, which may alter the biochemical pathways in which the protein is involved. The design of these inhibitors is often aided by advanced computational methods such as molecular docking and structure-activity relationship (SAR) studies, which help in predicting how the inhibitor will interact with the protein at the molecular level.
The development of V1RD16 inhibitors involves rigorous chemical synthesis and characterization processes. Researchers employ various organic synthesis techniques to assemble the inhibitor molecules with precision. Once synthesized, the inhibitors undergo a series of analyses to confirm their purity, structure, and stability. Techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and crystallography may be used to elucidate the molecular structure and to verify the integrity of the inhibitor. The physical and chemical properties, such as solubility, lipophilicity, and pKa, are also assessed, as these factors can influence the inhibitor's interaction with the V1RD16 protein. Additionally, in vitro studies are conducted to examine the binding efficiency and selectivity of the inhibitors towards their intended targets. These studies help ensure that the inhibitors are precisely tailored to interact with the V1RD16 proteins, which is fundamental to their role in the modulation of biochemical pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are upstream regulators in the Akt signaling pathway. Inhibition of PI3K leads to reduced Akt activation, which can subsequently decrease the functional activity of V1RD16. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, which irreversibly inhibits the enzyme, leading to suppression of the PI3K/Akt pathway. This inhibition is known to impact proteins regulated by Akt, potentially including V1RD16. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that impairs the mTORC1 complex, downstream of PI3K/Akt signaling. By inhibiting mTORC1, Rapamycin can reduce protein synthesis and cell growth, processes that may be crucial for the function of V1RD16. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which is a part of the MAPK/ERK pathway. By inhibiting MEK, PD98059 prevents the activation of ERK, which may influence the phosphorylation status and activity of V1RD16. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a non-competitive inhibitor of MEK1/2, also affecting the MAPK/ERK pathway. Through its action, it can indirectly lead to decreased activation or functionality of proteins that are regulated by this pathway, including V1RD16. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that specifically blocks the p38α and p38β isoforms. As p38 MAPK is involved in stress responses and cytokine production, its inhibition can affect proteins modulated by these signals, potentially including V1RD16. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is a component of the MAPK pathway. Inhibiting JNK can lead to alterations in transcription factor activities and cellular responses that may affect V1RD16's role in the cell. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor with broad specificity, including Src family kinases. By inhibiting these kinases, it can impact various signaling cascades, potentially influencing processes that govern the activity of V1RD16. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can affect protein degradation pathways. By modulating these pathways, it could lead to the accumulation of regulatory proteins that inhibit the function or signaling related to V1RD16. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide modulates the degradation of proteins by the E3 ubiquitin ligase complex. This modulation can lead to altered levels of proteins that regulate the cellular localization or stability of V1RD16, impacting its functional activity. | ||||||